Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Player FM - Aplicativo de podcast
Fique off-line com o app Player FM !
Fique off-line com o app Player FM !
Race Oncology receives positive results from AML trial of Bisantrene
MP3•Home de episódios
Manage episode 431551800 series 2891889
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
615 episódios
MP3•Home de episódios
Manage episode 431551800 series 2891889
Conteúdo fornecido por Proactive Investors. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Proactive Investors ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett sits down with Jonathan Jackson in the Proactive studio to discuss positive results from an investigator-sponsored Phase 1b/2 trial of RC110 bisantrene for acute myeloid leukaemia (AML). The trial, which included patients with relapsed or refractory AML, demonstrated a 40% response rate, exceeding the efficacy threshold. The open-label trial combined intravenous RC110 bisantrene with chemotherapies clofarabine and fludarabine. Out of the treated patients, five experienced complete responses and one had a partial response, surpassing the goal of at least three complete responses. Tillett expressed gratitude to Professor Nagler and the Chaim Sheba Medical Centre team for their dedication over the past five years. The team’s efforts have contributed significantly to the historical evidence supporting bisantrene’s efficacy and have spurred further interest among clinicians. The company plans to initiate a new Phase 1/2 investigator-sponsored trial using RC220 bisantrene, a reformulated version, to meet the high unmet needs of AML patients. Race Oncology is focused on anthracycline combinations, aiming to provide cardio-protection and enhanced anticancer activity in solid tumours, as well as offering low-intensity treatment options for AML. #ProactiveInvestors #RaceOncology #ASX #AML, #CancerTreatment, #Bisantrene, #ClinicalTrials, #PharmaNews, #OncologyResearch, #ChemoTherapy, #CancerResearch, #HealthNews, #MedicalResearch, #Phase1Trial, #Phase2Trial, #AcuteMyeloidLeukemia, #CancerCare, #MedicalBreakthrough, #Oncology, #Hematology, #DrugDevelopment, #PatientCare #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
615 episódios
Semua episode
×Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.